Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Authors' conclusion
Data in the CARRA Registry showed that etanercept treatment was safe in treating children with JPsA, with low AESIs and SAEs.
Study context
- Population
- Paediatric patients with juvenile psoriatic arthritis enrolled in the CARRA Registry who had used etanercept191 safety, 43 effectiveness analysis
- Participants
- 226 patients
- Outcome
- Safety: rates of prespecified adverse events of special interest (AESIs) and serious adverse events (SAEs); effectiveness by disease activity measures
Methodological detailsCARRA Registry, clinical practice data
- CARRA Registry
- Clinical practice data
Main finding
As reported in the abstract
AESIs and SAEs
- Total events (3 uveitis, 1 new-onset neuropathy, 1 malignancy)
- 5
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| ACR-Pediatric Response 90 · 6-month follow-up | Etanercept 46.7% |
| Clinical Juvenile Arthritis Disease Activity Score 10-joint ≤1.1 · 6-month follow-up | Etanercept 36.0% |
| Clinically inactive disease · 6-month follow-up | Etanercept 51.9% |
- ACR-Pediatric Response 90: 7 of 15
- Clinical Juvenile Arthritis Disease Activity Score 10-joint ≤1.1: 9 of 25
- Clinically inactive disease: 14 of 27
Safety
Uveitis
- Events
- 3
- Incidence rate per 100 patient-years
- 0.55 (95% CI 0.18, 1.69)
New-onset neuropathy
- Events
- 1
- Incidence rate per 100 patient-years
- 0.18 (95% CI 0.03, 1.29)
Malignancy
- Events
- 1
- Incidence rate per 100 patient-years
- 0.13 (95% CI 0.02, 0.09)
Original publication
Occurrence of adverse events and change in disease activity after initiation of etanercept in paediatric patients with juvenile psoriatic arthritis in the CARRA Registry. RMD Open. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →